HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea
· Delayed Price · Currency is KRW 2,945.00
+85.00 (2.97%)
Mar 10, 2026, 10:30 AM KST
HLB Therapeutics Revenue
HLB Therapeutics had revenue of 16.06B KRW in the quarter ending September 30, 2025, with 14.32% growth. This brings the company's revenue in the last twelve months to 63.25B, up 16.82% year-over-year. In the year 2024, HLB Therapeutics had annual revenue of 54.93B with 4.45% growth.
Revenue (ttm)
63.25B
Revenue Growth
+16.82%
P/S Ratio
3.80
Revenue / Employee
1.29B
Employees
49
Market Cap
240.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.93B | 2.34B | 4.45% |
| Dec 31, 2023 | 52.59B | 10.19B | 24.03% |
| Dec 31, 2022 | 42.40B | -1.18B | -2.72% |
| Dec 31, 2021 | 43.59B | 656.63M | 1.53% |
| Dec 31, 2020 | 42.93B | -16.04B | -27.20% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EASY BIO,Inc. | 465.24B |
| Genexine | 5.81B |
| Helixmith | 3.74B |
| iNtRON Biotechnology | 5.56B |
| Vaxcell-Bio Therapeutics | 1.90B |
| Macrogen | 179.98B |
| JETEMA, | 75.55B |
| Bioneer | 320.69B |